Sanofi is a French pharmaceutical company that develops and sells prescription drugs, with its strongest positions in immunology, vaccines, and rare diseases. Its biggest product, Dupixent (an antibody treatment for conditions like eczema and asthma), generates over 30% of total revenue, with profits split with Regeneron. The remaining revenue comes from a range of other drugs and vaccines sold globally. Customers are patients and healthcare systems; the company earns money through drug sales, with roughly half coming from the U.S.
Employees74,846IPOJul 1, 2002HQ46, Avenue de la Great Army, Paris, FRA, 75017
to
Financials
Profitability
Metric
Current
Margins
Gross Margin
72.8%
Operating Margin
20.6%
EBITDA Margin
26.5%
Net Margin
8.1%
OCF Margin
24.2%
FCF Margin
17.2%
Returns on Capital
ROE
5.6%
ROA
3.1%
ROIC
6.8%
ROCE
6.3%
ROC (Greenblatt)
53.6%
3Y ROIIC
−12.0%
Consistency
Years Profitable / 10Y
10
Valuation
Metric
Current
Earnings Multiples
P/E (TTM)
21.40
Forward P/E
8.21
P/E ex-NRI
11.53
Shiller P/E (CAPE)
12.13
Cash Flow Multiples
P/FCF
10.17
P/OCF
7.20
P/Owner Earnings
8.10
FCF Yield
10.07%
Enterprise Value Multiples
EV / EBIT
16.51
EV / Forward EBIT
9.92
EV / EBITDA
7.85
EV / Forward EBITDA
8.06
EV / Revenue
2.07
EV / Forward Revenue
2.00
Asset / Sales
P/S
1.74
P/B
1.23
P/Tangible Book
94.44
Growth-Adjusted
PEG
—
Capital Returns
Metric
Current
Dividends
Dividend Yield (TTM)
5.92%
Forward Dividend Yield
5.92%
3Y Dividend Growth
5.6%
Payout Ratio
0.68
5Y Yield on Cost
6.76%
Buybacks & Dilution
3Y Buyback Ratio
1.40%
5Y Share Change
−2.7%
Combined
Shareholder Yield
6.06%
Balance Sheet
Metric
Current
Leverage
Debt / Equity
0.34
Gross Debt / EBITDA
1.82
Cash / Debt
0.27
Equity / Assets
0.54
Coverage
Interest Coverage
13.80
Short-Term Liquidity
Current Ratio
0.99
Quick Ratio
0.64
Cash Ratio
0.20
Composite Scores
Piotroski F-Score
7
Altman Z-Score
1.57
Split History
Date
Split
No split history found.
Ex-date
Amount
Pay date
2026-05-04
$2.42
2026-06-03
2025-05-09
$2.2
2025-06-12
2024-05-09
$2.04
2024-06-06
2023-05-30
$1.9
2023-06-23
2022-05-26
$0.2972
2022-06-27
2022-05-04
$1.75
2022-05-31
2021-05-03
$1.93
2021-05-26
2020-04-30
$1.7
2020-05-26
2019-05-07
$1.72
2019-05-31
2018-05-09
$1.79
2018-06-04
10 of 27
View allDate
Transcript
Type
2026-07-30
Q2 2026 Sanofi SA Earnings Call Transcript
Earnings Call
2026-04-23
Q1 2026 Sanofi SA Earnings Call Transcript
Earnings Call
2026-01-29
Q4 2025 Sanofi SA Earnings Call Transcript
Earnings Call
2026-01-12
Sanofi SA at JPMorgan Healthcare Conference Transcript
Conference Presentations
2025-12-02
Sanofi SA at Citi Global Healthcare Conference Transcript
Conference Presentations
2025-10-24
Q3 2025 Sanofi SA Earnings Call Transcript
Earnings Call
2025-07-31
Q2 2025 Sanofi SA Earnings Call Transcript
Earnings Call
2025-04-24
Q1 2025 Sanofi SA Earnings Call Transcript
Earnings Call
2025-01-30
Q4 2024 Sanofi SA Earnings Call Transcript
Earnings Call
2024-10-25
Q3 2024 Sanofi SA Earnings Call Transcript
Earnings Call
10 of 94
5-Step DuPont Analysis
ROE %
5.73%
×
×
Net Margin %
8.09%
×
×
Operating Margin %
20.61%
Operating Income
$11.71B
÷
Revenue
$56.84B
×
Tax Burden
0.7289
Net Income
$4.60B
÷
Pretax Income
$6.31B
×
Interest Burden
0.5386
Pretax Income
$6.31B
÷
Operating Income
$11.71B
×
Asset Turnover
0.39
÷
Revenue
$56.84B
÷
Average Total Assets
$146.41B
Begin Total Assets
$144.13B
End Total Assets
$148.69B
×
Equity Multiplier
1.82
÷
Avg Total Assets
$146.41B
÷
Avg Stockholders Equity
$80.24B
Begin Equity
$80.75B
End Equity
$79.73B
Top institutional holders
Q2 2026| Holder | Shares | % Owned | Chg. shares | |
|---|---|---|---|---|
| Dodge & Cox | 28.1M | 1.17% | -1.4M | $1.20B |
| MORGAN STANLEY | 10.7M | 0.44% | -1.8M | $456.57M |
| Fisher Asset Management, LLC | 10.6M | 0.44% | -815.1K | $453.35M |
| BANK OF AMERICA CORP /DE/ | 8.0M | 0.33% | -1.5M | $341.65M |
| Invesco Ltd. | 6.8M | 0.28% | +177.4K | $290.04M |
| JPMORGAN CHASE & CO | 6.6M | 0.27% | +973.0K | $285.50M |
| Mondrian Investment Partners LTD | 5.5M | 0.23% | +482.5K | $235.59M |
| BRANDES INVESTMENT PARTNERS, LP | 4.1M | 0.17% | +413.3K | $176.46M |
| FEDERATED HERMES, INC. | 3.8M | 0.16% | -904.6K | $164.23M |
| Boston Partners | 3.8M | 0.16% | +245.6K | $164.04M |
10 of 724
View all